Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 122
- Registration Number
- NCT01773408
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Cancer Therapy & Research Ctr; Dept Institute for Drug Development, San Antonio, Texas, United States
🇨🇦McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 255
- Registration Number
- NCT01546038
- Locations
- 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
🇺🇸University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
🇺🇸LAC & USC Medical Center, Los Angeles, California, United States
Protocol in Acute Myeloid Leukemia With FLT3-ITD
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 451
- Registration Number
- NCT01477606
- Locations
- 🇦🇹
Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 29
- Registration Number
- NCT01463046
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01451515
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 19
- Registration Number
- NCT01390337
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
- Conditions
- Interventions
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 51
- Registration Number
- NCT01004497
- Locations
- 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00866749
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00853008
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Clínica Teknon, Barcelona, Spain
🇪🇸Hospital de Fuenlabrada, Madrid, Spain
Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 89
- Registration Number
- NCT00850382
- Locations
- 🇦🇹
Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹Elisabethinen Krankenhaus, Linz, Austria
🇦🇹Universitätsklinikum Innsbruck, Innsbruck, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.